APPENDICES. A systematic review and economic model of the ...

More documents

Recommendations

Info

248 Appendix 12 Core symptoms Educational performance Quality of life Adverse events Not reported Not reported Not reported Mean severity rating by parents (17 side effects): Low-dose MPH High-dose MPH Placebo Trouble sleeping 2.89 (2.33) 2.61 (2.45) 1.69 (2.68) NS Nightmares 0.39 (0.60) 0.43 (0.88) 0.33 (0.77) NS Stares/daydreams 1.72 (1.43) 1.07 (1.33) 1.09 (1.33) NS Talks less with others 0.80 (0.81) 1.27 (1.53) 1.17 (2.38) NS Interested in others 0.52 (0.74) 1.34 (1.34) 0.76 (1.23) NS Decreased appetite 2.23 (1.34) 3.09 (3.09) 1.33 (1.38) F = 13.0, p = 0.002 Irritable 3.71 (2.19) 2.98 (2.85) 2.69 (2.39) NS Stomach ache 0.81 (1.68) 2.32 (3.35) 1.06 (2.25) NS Headache 0.17 (0.30) 1.39 (2.55) 0.81 (1.64) NS Drowsiness 0.24 (0.30) 0.73 (0.99) 0.63 (1.62) Sad 1.52 (1.56) 2.77 (3.12) 1.65 (1.98) NS Crying 2.11 (2.16) 3.30 (3.54) 1.97 (2.21) NS Anxious 2.91 (2.37) 3.16 (3.46) 3.26 (2.97) NS Bites nails 0.67 (1.71) 1.27 (2.34) 0.63 (1.82) NS Euphoric 0.78 (1.19) 1.21 (1.56) 1.35 (1.63) NS Dizziness 0.11 (0.28) 0.91 (1.26) 0.28 (0.71) NS Conclusions Authors’ conclusions: Several side-effects appeared equally often on placebo as on active medication and the parents’ reports of side-effects are significantly related to reports of ADHD symptomology Reviewer’s comments: No comments noted
Study Intervention Participants Outcomes Core symptoms CTRS: Hyperactivity Index Reference Firestone et al., 1986 53 Co-existent problems Quay–Peterson Behaviour Problem Checklist: conduct problem Inclusion criteria 1. 5–9 years of age 2. Demonstration of symptoms before 3 years old 3. A rating of 1.5 on the Teachers Hyperactivity Index 4. IQ of ≥ 85 or greater (Peabody Picture Vocabulary) 5. No signs of brain damage, epilepsy or psychosis Source AHRQ Report Educational performance Gates–MacGinitie Reading Test Vocabulary Grade (GMVG) Arm 1 MPH plus non-drug intervention Average of 22 mg/day with a maximum of 30 mg and minimum of 10 mg; administered twice daily (a.m., noon). Parent training involved sessions and group meetings on child management and learning how to cooperate efficiently with school personnel (Administered by parent and medical personnel) Setting Canada Design Parallel trial Psychological function Mean reaction time Diagnostic criteria DSM-III Number Total randomised = 134 (male/female split not reported) Numbers in each arm not reported Depression or anxiety Not reported Quality of life Not reported Total analysed at post-test (3 months) = 73 Arm 1 = 22 Arm 2 = 21 Arm 3 = 30 Arm 2 Placebo plus non-drug intervention Parent training (Administered by parent and medical personnel) Adverse events Not reported Additional outcomes Not reported Total with follow-up data (2 years) = 52 Total analysed at follow-up = 30 Arm 1 = 10 Arm 2 = 9 Arm 3 = 11 (22 had switched from their original treatment condition) Duration Trial length: 3 months; follow-up: 2 years. Purpose Not explicitly stated. The authors examine long-term outcomes (2 years) of a 3-month trial that compared stimulant medication alone, stimulant medication plus parents trained in behaviour modification and placebo plus parent training © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Arm 3 MPH Average of 22 mg/day with a maximum of 30 mg and minimum of 10 mg; administered twice daily (a.m., noon). (Administered by parent) Health Technology Assessment 2006; Vol. 10: No. 23 Age 5–9 years (range) IQ Not reported Co-morbid disorders Not reported Diagnostic subtypes Not reported Additional information No relevant information reported 249
Page 1 and 2:
Appendices A systematic review and
Page 3 and 4:
Clinical effectiveness information
Page 5 and 6:
Searches for systematic reviews in
Page 7 and 8:
19. methyl phenidate.mp. 20. methyl
Page 9 and 10:
43. attention deficit$.mp. 44. 42 o
Page 11 and 12:
MEDLINE in-process and other non-in
Page 13 and 14:
PsycINFO (1967-July 2004) Searched:
Page 15 and 16:
next aminopropane) or dynaphenyl or
Page 17 and 18:
or ritaline or riphenidate or rital
Page 19:
System for Information on Grey Lite
Page 22 and 23:
166 Appendix 2 S hyperkinetic S imp
Page 24 and 25:
168 Appendix 2 19. (eq5d or eq 5d o
Page 26 and 27:
170 Appendix 2 14. (person trade of
Page 28 and 29:
172 Appendix 3 Reference Reason for
Page 31:
Appendix 4 © Queen’s Printer and
Page 34 and 35:
178 Appendix 5 8. Was the statistic
Page 36 and 37:
180 Appendix 6 Cost-effectiveness R
Page 38 and 39:
182 Appendix 7 Appropriateness of m
Page 40 and 41:
184 Appendix 7 Sensitivity analysis
Page 42 and 43:
186 Appendix 7 Sensitivity analysis
Page 44 and 45:
188 Appendix 8 Probability cost-eff
Page 47 and 48:
Appendix 10 © Queen’s Printer an
Page 49 and 50:
Health state Responder to ATX, no s
Page 51 and 52:
Health state Responder to IR-MPH, R
Page 53 and 54: Health state Responder to ER-MPH, R
Page 55: #Baseline shift random effects mode
Page 58 and 59: 202 Appendix 12 Study Intervention
Page 62 and 63: 206 Appendix 12 Core symptoms Educa
Page 154 and 155:
298 Appendix 12 Core symptoms Educa
Page 156 and 157:
300 Appendix 12 Study Intervention
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222:
366 Appendix 13 Study characteristi
show all

APPENDICES. A systematic review and economic model of the ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?